Zeller International | zeller
Phytopharm Congress 2018 – a great success
Phytopharm Congress 2018 – a great success Phytopharm Congress 2018 – a great success

Phytopharm Congress 2018 – a great success

“The Phytopharm Congress bridges the gap between academia, industry and authorities”, explained Dr Georg Boonen, CEO of Zeller, summing up why this event has become an important platform for scientific exchange in the field of natural and medicinal plant research.

July 11, 2018

Phytopharm Congress 2018 – a great success

“The Phytopharm Congress bridges the gap between academia, industry and authorities”, explained Dr Georg Boonen, CEO of Zeller, summing up why this event has become an important platform for scientific exchange in the field of natural and medicinal plant research.

July 11, 2018

The 22nd Phytopharm Congress 2018 was once again a great success: attracting about 275 participants from more than 40 countries. The congress, organized by the St. Petersburg Institute of Pharmacy together with Zurich University of Applied Sciences (ZHAW), took place for the first time in Switzerland. International experts from leading universities and industries presented over 60 lectures and more than a 100 posters to share their latest insights on medicinal plants, natural products and evidence-based phytotherapy. Topics on quality assurance and regulations of herbal medicinal products and food supplements were also covered.

Zeller, as a main supporter of the Phytopharm Congress 2018, made important contributions to this success with talks and poster presentations on new research data. “Research and Development is very important to Zeller. Our products are based on evidence and evidence is based on data”, stated Dr Boonen. Further, Zeller contributed to the congress program with a full-day excursion to the Zeller head offices in Romanshorn and to VitaPlant AG, a subsidiary of Zeller. Under the motto “Zeller World – From Seed to Patient”, 65 congress participants had the opportunity to learn more about the development of evidence-based phyto-pharmaceuticals. In a seminar titled “The Development of a New Herbal Entity” Zeller`s Petasites hybridus extract Ze 339 for the treatment of allergic rhinitis was presented. From controlled plant cultivation through phytochemical analysis, preclinical and clinical studies to drug approval, Zeller demonstrated control of the entire value chain. In the afternoon, the excursion continued at VitaPlant. In a guided tour, the participants were able to see the selected and cultured elite plants in Zeller-VitaPlant’s fields and greenhouses. A highlight was the visit to the medicinal plant garden. “It is very impressive to see Zeller translating the science into something that benefits the society”, says Dr Robert Verpoorte, emeritus professor for Pharmacognosy, University of Leiden.

3H5A2172.jpg
3H5A2800.jpg
DSC00400.jpg

Topics

Filter blog posts by topic by clicking on the tags.

Matching posts